What is the recommended dose, contraindications, and alternatives for cinnarizine?

Cinnarizine: Dosing, Contraindications, and Alternatives

Cinnarizine is typically dosed at 25-30 mg three times daily for vestibular vertigo and motion sickness, with a maximum of 150 mg/day, though the fixed low-dose combination of cinnarizine 20 mg plus dimenhydrinate 40 mg three times daily demonstrates superior efficacy and should be preferred when available.

Recommended Dosing

Standard Monotherapy

• Motion sickness (adults): 30 mg taken 2 hours before travel, then 15 mg every 8 hours as needed 1
• Motion sickness (children): 15 mg taken 2 hours before travel, then 7.5 mg (half tablet) every 8 hours as needed 1
• Seasickness prevention: 50 mg as a single dose (25 mg was ineffective in controlled trials) 2
• Vestibular vertigo: 25-75 mg twice daily 3

Fixed-Dose Combination (Preferred)

Cinnarizine 20 mg + dimenhydrinate 40 mg: Take three times daily 4, 5. This combination demonstrates:

• Significantly greater reduction in Mean Vertigo Score (MVS) compared to betahistine, with differences ranging from 0.16 to 0.60 points (p < 0.05) 4
• 24.7% of patients completely symptom-free after 4 weeks versus lower rates with all comparators 4
• Efficacy evident from week 1, sustained through 60 days 6, 5
• Superior tolerability with 97.9% rating it "good" or "very good" 4

Contraindications and Cautions

Absolute Contraindications

• Aircrew and pilots: Cinnarizine causes measurable CNS depression, impaired performance, and reduced sleep latencies at all therapeutic doses (15-45 mg), persisting 5-8 hours post-ingestion 7
• Tasks requiring sustained attention: Performance impairment documented at 30-45 mg doses 7

Relative Contraindications and Warnings

• Parkinson's disease: Cinnarizine is a calcium channel blocker that may theoretically affect dopaminergic pathways, though recent research suggests potential neuroprotective effects 8
• Hepatic impairment: Use with caution; no dose adjustment guidelines exist, but metabolism may be impaired 9
• Renal impairment: Monitor for drug accumulation, particularly in elderly patients 9
• Elderly patients: Start at lower doses due to age-related decline in renal function 9
• Pregnancy: Limited human data; animal studies at 25 mg/kg (2× human dose) showed fetal malformations 9

Common Adverse Effects

• Sedation/drowsiness: Dose-dependent; 14% reported sleepiness at 15 mg in children 1, increased at higher doses 7
• CNS effects: Reduced sleep latencies at 3.5-5 hours post-dose even at 15 mg 7
• Overall incidence of adverse events: 6.9% in pooled trials, with only 2.4% discontinuing treatment 4

Alternatives

First-Line Alternatives

1. Betahistine

• Dosing: 16 mg three times daily or 24 mg twice daily 3
• Evidence: Less effective than cinnarizine/dimenhydrinate combination across multiple meta-analyses 4, 6
• Best for: Ménière's disease specifically, where it shows good efficacy 3
• Advantage: No sedation, suitable for patients requiring alertness

2. Dimenhydrinate Monotherapy

• Dosing: 40-100 mg as needed 4
• Evidence: Less effective than the fixed combination with cinnarizine 4
• Best for: Acute motion sickness when cinnarizine unavailable

3. Meclizine (Note: Evidence provided was for meclizine, not cinnarizine)

• Dosing: 25-100 mg daily in divided doses 9
• Cautions: Similar CNS effects; use cautiously in elderly, hepatic/renal impairment 9

Second-Line Options

Prochlorperazine

• Dosing: 5-10 mg every 6-8 hours or 25 mg suppository every 12 hours 10, 11
• Cautions: Extrapyramidal symptoms, anticholinergic effects, contraindicated in dementia 10
• Best for: Acute vertigo with severe nausea/vomiting

Promethazine

• Dosing: 12.5-25 mg every 4-6 hours 10, 11
• Cautions: Significant sedation, tissue injury risk with peripheral IV administration 10

Clinical Algorithm

For vestibular vertigo:

1. First choice: Cinnarizine 20 mg + dimenhydrinate 40 mg three times daily 4, 5
2. If unavailable: Cinnarizine 25-30 mg three times daily
3. If sedation problematic: Betahistine 16 mg three times daily 3
4. For Ménière's disease specifically: Consider betahistine as first-line 3

For motion sickness:

1. Adults: Cinnarizine 30 mg 2 hours pre-travel, then 15 mg every 8 hours 1
2. Severe seasickness: Cinnarizine 50 mg single dose 2
3. Children: Cinnarizine 15 mg 2 hours pre-travel, then 7.5 mg every 8 hours 1

Avoid cinnarizine entirely in:

• Pilots and aircrew 7
• Operators of heavy machinery during treatment hours 0-8 7
• Patients requiring tasks demanding sustained attention 7

Key Pitfalls

• Underdosing for seasickness: 25 mg cinnarizine is ineffective; 50 mg required 2
• Using monotherapy when combination available: The fixed combination consistently outperforms either agent alone 4, 6
• Ignoring timing: Cinnarizine requires 2-hour pre-exposure administration for motion sickness 1
• Overlooking CNS effects: Even "therapeutic" 15 mg doses cause measurable impairment 7
• Gender considerations: Emerging evidence suggests differential responses between males and females, though clinical significance requires further study 5